摘要
目的：研究帕洛诺司琼对大鼠体内奥沙利铂药动学的影响。方法：雄性Wistar大鼠随机分为2组（n=10），对照组只给奥沙利铂，给药剂量为23．11mg·kg^-1实验组在给奥沙利铂前30min给予帕洛诺司琼0．03mg·kg^-1。2组大鼠分别于给药前和给药后0，5，15，30，45，60，120，180min取血，HPLC法测定血浆奥沙利铂浓度，用统计矩法计算药动学参数。结果：奥沙利铂检测浓度的线性范围为2．0～160．0μg·ml^-1（r=0．9995），方法回收率为101．6％～112．7％，日内、日间RSD均〈5％。对照组和实验组奥沙利铂的药动学参数分别为：AUC（0-∞）（12．67±1．69）mg·h·L^-1，（11．97±1．41）mg·h·L^-1；Cmax（72．82±12．09）mg·L^-1，（70．12±14．22）mg·L^-1；t1／2z：（0．550±0．210）h，（0．671±0．333）h。各项参数均无统计学差异（P〉0．05）。结论：奥沙利铂单独使用及与帕洛诺司琼合用的药动学参数之间没有显著性差异。帕洛诺司琼对奥沙利铂在大鼠体内的药动学没有影响。
OBJECTIVE To investigate the influence of plalonosetron on the pharmacokinetics of oxaliplatin in rats. METHODS Rats were divided into two groups （n = 10） randomly and treated with doses of oxaliplatin （23. 11 mg·kg^-1 ）. No antie- metic agents were administered to the control group. The experimental group received 0. 03mg·kg^-1 of plalonosetron before 30 min administration of oxaliplatin. In each of the group, blood samples were obtained for pharmacokinetic study at the following times： 0, 5, 15, 30, 45, 60,120,180 min before and after the start of the oxaliplatin infusion. RESULTS The linear range of oxaliplatin was 2. 0-160. μg·ml^-1 （r = 0. 999 5）with an average extraction recovery of 101. 6%-112. 7% . The RSD of in- tra-day and inter-day were all lower then 5 %. The pharmacokinetic parameters of oxaliplatin in control group vs. trail groups were as follows： AUC（0 -∞） （ 12. 67 ± 1.69） mg·h·L^-1 , （ 11.97 ± 1. 41 ） mg·h·L^-1; Cmax ： （72. 82 ± 12. 09） mg·L^-1 , （70. 12 ± 14. 22）mg·L^-1;t1/2z：（0. 550 ± 0. 210） h, （0. 671 ± 0. 333） h. There was no statistical significance in pharmacokinetic parameters between the single dose of oxaliplatin and the combination of plalonosetron, CONCLUSION No significant difference was found in our study between the pharmacokinetic parameters of oxaliplatin after the single dose of oxaliplatin and the combination of plalonosetron.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2014年第7期534-537,共4页
Chinese Journal of Hospital Pharmacy
